Advertisement

Foamy Viruses pp 131-159 | Cite as

Foamy Virus Vectors

Chapter
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 277)

Abstract

Successful treatment for diseases such as cancer and AIDS will likely involve particular combinations of drug therapy, immunotherapy, and gene therapy. Gene therapy is a novel approach currently under development for treatment of a variety of diseases (Anderson 1998). This novel therapy offers a fresh alternative, which endows a therapeutic effect by introduction of a particular gene into targeted cells. The effect of gene therapy in the host will depend, in part, on the efficiency of the vector system used to deliver the effector molecule. Numerous vector constructions have been used to deliver and express genes in human cells. Biological vectors for gene therapy are constructed from several viruses that include herpes simplex virus type 1, adenovirus, adenoassociated virus, and retroviruses (Kay et al. 2001; Robbins et al. 1998; Romano et al. 2000; Smith 1999; Wolfe et al. 1999; Wu and Ataai 2000). Among these vectors, retroviruses are most widely used as an efficient means for introducing foreign DNA into the cell genome. The life cycle of retroviruses involves stable integration of viral genetic material into the host genome; expression of viral genes is, in part, regulated by host cell factors (Coffin et al. 1997). These features of retroviruses make them useful for selected applications of gene transfer in animals and humans. Retroviral vectors are significant for basic biological investigations such as studies of cell lineage, mechanisms of carcinogenesis, and developmental and tissue-specific regulation of defined DNA sequences as well as clinical uses for gene therapy (Varmus 1988). Clinical applications of retroviral

Keywords

Human Immunodeficiency Virus Type Long Terminal Repeat Foamy Virus Nondividing Cell Packaging Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bock M, Heinkelein M, Lindemann D, Rethwilm A (1998) Cells expressing the human foamy virus (HFV) accessory Bet protein are resistant to productive HFV superinfection. Virology 250:194-204PubMedGoogle Scholar
  2. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M (1992) Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci USA 89:6580-6584PubMedGoogle Scholar
  3. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Nail Acad Sci USA 90:8033-8037Google Scholar
  4. Cain D, Erlwein O, Grigg A, Russell RA and McClure MO (2001) Palindromic sequence plays a critical role in human foamy virus dimerization. J Virol 75:3731-3739PubMedGoogle Scholar
  5. Callahan ME, Switzer WM, Matthews AL, Roberts BD, Heneine W, Folks TM, Sandstrom PA (1999) Persistent zoonotic infection of a human with simian foamy virus in the absence of an intact orf-2 accessory gene. J Virol 73:9619-9624PubMedGoogle Scholar
  6. Campbell M, Renshaw-Gegg L, Renne R, Luciw PA (1994) Characterization of the internal promoter of simian foamy viruses. J Virol 68:4811-4820PubMedGoogle Scholar
  7. Cavazzana-Calvo M, Hacein-Bey S, de-Saint-Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-72PubMedGoogle Scholar
  8. Charneau P, Alizon M, Clavel F (1992) A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication. J Virol 66:2814-2820PubMedGoogle Scholar
  9. Civin C (2000) Gene therapy in clinical applications. Stem Cells 180:150-156Google Scholar
  10. Clavel F, Orenstein JM (1990) A mutant of human immunodeficiency virus with re- duced RNA packaging and abnormal particle morphology. J Virol 64:5230-5234PubMedGoogle Scholar
  11. Clever JL, Parslow TG (1997) Mutant human immunodeficiency virus type 1 gen- omes with defects in RNA dimerization or encapsidation. J Virol 71:3407-3414PubMedGoogle Scholar
  12. Coffin JM, Hughes SH, Varmus HE, eds (1997) Retroviruses. Cold Spring Harbor Laboratory Press, New YorkGoogle Scholar
  13. Eglitis MA, Anderson WF (1988) Retroviral vectors for introduction of genes into mammalian cells. BioTechniques 6:608-614PubMedGoogle Scholar
  14. Enssle J, Fischer N, Moebes A, Mauer B, Smola U, Rethwilm A (1997) Carboxy-terminal cleavage of the human foamy virus gag precursor molecule is an essential step in the viral life cycle. J Virol 71:7312-7317PubMedGoogle Scholar
  15. Erlwein O, Bieniasz PD, McClure MO (1998) Sequences in pol are required for transfer of human foamy virus-based vectors. J Virol 72:5510-5516PubMedGoogle Scholar
  16. Erlwein O, Cain D, Fischer N, Rethwilm A, McClure MO (1997) Identification of sites that act together to direct dimerization of human foamy virus RNA in vitro. Virology 229:251-258PubMedGoogle Scholar
  17. Fauci AS (1996) Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-534PubMedGoogle Scholar
  18. Federico M (1999) Lentiviruses as gene delivery vectors. Curr Opin Biotechnol 10:448-453PubMedGoogle Scholar
  19. Fischer N, Heinkelein M, Lindemann D, Enssle J, Baum C, Werder E, Zentgraf H, Muller JG, Rethwilm A (1998) Foamy virus particle formation. J Virol 72:16101615Google Scholar
  20. Flügel RM (1991) Spumaviruses: a group of complex retroviruses. J AIDS 4:739-750Google Scholar
  21. Flügel RM, Rethwilm A, Maurer B, Darai G (1987) Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes. EMBO J 6:2077-84PubMedGoogle Scholar
  22. Gallay P, Stitt V, Mundy C, Oettinger M, Trono D (1996) Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol 70:1027-1032PubMedGoogle Scholar
  23. Giron ML, Rozain F, Debons-Guillemin MC, Canivet M, Perks J, Emanoil-Ravier R (1993) Human foamy virus polypeptides: identification of env and bel gene products. J Virol 67:3596-3600PubMedGoogle Scholar
  24. Gunji Y, Ochiai T, Shimada H, Matsubara H (2000) Gene therapy for cancer. Surg Today 30:967-73PubMedGoogle Scholar
  25. Hahn H, Gerald B, Brautigam S, Mergia A, Neumann-Haefelin D, Daniel MD, McClure MO, Rethwilm A (1994) Reactivity of primate sera to foamy virus Gag and Bet proteins. J Gen Virol 75:2635-2644PubMedGoogle Scholar
  26. He F, Sun JD, Garrett ED, Cullen BR (1993) Functional organization of the Bel-1 transactivator of human foamy virus. J Virol 67:1896-1904PubMedGoogle Scholar
  27. Heinkelein M, Schmidt M, Fischer N, Moebes A, Lindemann D, Enssle J, Rethwilm A (1998) Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J Virol 72:6307-6314PubMedGoogle Scholar
  28. Heinkelein M, Thurow J, Dressler M, Imrich H, Neumann-Haefelin D, McClure MO, Rethwilm A (2000a) Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging. J Virol 74:3141-3148PubMedGoogle Scholar
  29. Heinkelein M, Pietschmann T, Jarmy G, Dressler M, Imrich H, Thurow J, Lindemann D, Bock M, Moebes A, Roy J, Herchenröder O and Rethwilm A (2000b) Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO J 19:3436-3445PubMedGoogle Scholar
  30. Heinkelein M, Dressler M, Jarmy G, Rammling M, Imrich H, Thurow J, Lindemann D and Rethwilm A (2002a) Improved primate foamy virus vectors and packaging constructs. J Virol 76:3774-3783PubMedGoogle Scholar
  31. Heinkelein M, Leurs C, Rammling M, Peters K, Hanenberg H and Rethwilm A (2002b) Pregenomic RNA is required for efficient incorporation of Pol polyprotein into foamy virus capsids. J Virol 76:(in press)Google Scholar
  32. Heneine W, Switzer WM, Sandstrom P, Brown J, Vedapuri S, Schable CA, Khan AS, Lerche NW, Schweizer M, Neumann-Haefelin D, Chapman LE, Folks TM (1998) Identification of a human population infected with simian foamy viruses. Nat Med 4:403-407PubMedGoogle Scholar
  33. Herchenröder O, Renne R, Loncar D, Cobb EK, Murthy KK, Schneider J, Mergia A, Luciw PA (1994) Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). Virology 201:187-199PubMedGoogle Scholar
  34. Herchenröder O, Turek R, Neumann-Haefelin D, Rethwilm A, Schneider J (1995) Infectious proviral clones of chimpanzee foamy virus (SFVcpz) generated by long PCR reveal close functional relatedness to human foamy virus. Virology 214:685-689PubMedGoogle Scholar
  35. Hildinger M, Abel KL, Ostertag W and Baum C (1999) Design of 5' untranslated se- quences in retroviral vectors developed for medical use. J Virol 73:4083-4089PubMedGoogle Scholar
  36. Hill CL, Bieniasz PD, McClure MO (1999) Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 80:2003-2009PubMedGoogle Scholar
  37. Hirata RK, Miller AD, Andrews RG, Russell DW (1996) Transduction of hematopoi- etic cells by foamy virus vectors. Blood 88:3654-3661PubMedGoogle Scholar
  38. Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, Deist Fl, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A, Harvey M, Levinsky RJ, Valerio D (1996) Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 3:179-83PubMedGoogle Scholar
  39. Hooks JJ, Detrick-Hooks B (1981) Spumavirinae: foamy virus group infections. Comparative aspects and diagnosis. In: Kurstak E, Kurstak C (eds) Comparative Diagnosis of Viral Disease. Academic Press, New YorkGoogle Scholar
  40. Josephson NC, Vassilopoulos G, Trobridge GD, Priestley GV, Wood BL, Papayannopoulou T, Russell DW (2002) Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 99:8295-8300PubMedGoogle Scholar
  41. Kantoff PW, Freeman SM, Anderson WF (1988) Prospects for gene therapy for immunodeficiency diseases. Annu Rev Immunol 6:581-594PubMedGoogle Scholar
  42. Kaplan AH, Swanstrom R (1991) Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Nad Acad Sci USA 88:4528-4532Google Scholar
  43. Katz RA, Terry RW, Skalka AM (1986) A conserved cis-acting sequence in the 5' lead- er of avian sarcoma virus RNA is required for packaging. J Virol 59:163-167PubMedGoogle Scholar
  44. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature Med 7:33-40PubMedGoogle Scholar
  45. Keller A, Partin KM, Löchelt M, Bannert H, Flügel RM, Cullen BR (1991) Characterization of the transcriptional trans-activator of human foamy virus. J Virol 65:2589-2594PubMedGoogle Scholar
  46. Kim HJ, Lee K, O'Rear JJ (1994) A short sequence upstream of the 5“ major splice site is important for encapsidation of HIV-1 genomic RNA. Virology 198:336-340PubMedGoogle Scholar
  47. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ (1998) Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 72:811-816PubMedGoogle Scholar
  48. Klimatcheva E, Resenblatt JD, Planelles V (1999) Lentiviral vectors and gene therapy. Front Biosci 4:D482-496Google Scholar
  49. Konvalinka J, Löchelt M, Zentgraf H, Flügel RM, Kräusslich HG (1995) Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol 69:7264-7268PubMedGoogle Scholar
  50. Kouraklis G (2000) Gene therapy for cancer: from the laboratory to the patient. Dig Dis Sci 45:1045-1052Google Scholar
  51. Kräusslich HG, Ochsenbauer C, Traenckner AM, Mergener K, Facke M, Gelderblom HR, Bosch V (1993) Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology 192:605-617PubMedGoogle Scholar
  52. Kupiec J, Kay A, Hayat M, Ravier R, Perks J, Galibert F (1991) Sequence analysis of the simian foamy virus type 1 genome. Gene 101:185-194PubMedGoogle Scholar
  53. Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M, Lindemann D, von Kalle C, Rethwilm A, Williams DA, Hanenberg H (2002) Comparison of three retroviral vector systems for transduction of NOD/SCID repopulating CD34+ cord blood cells (submitted)Google Scholar
  54. Lever A, Göttlinger H, Haseltine W, Sodroski J (1989) Identification of a sequence required for efficient packaging of human immunodeficiency virus type 1 RNA into virions. J Virol 63:4085-4087PubMedGoogle Scholar
  55. Levy J (1993) Pathogenesis of human immunodeficinecy virus infection. Microbiol Rev 57:183-289PubMedGoogle Scholar
  56. Lewis PF, Emerman M (1994) Passage through mitosis is required for oncoretro- viruses but not for the human immunodeficiency virus. J Virol 68:510-516PubMedGoogle Scholar
  57. Lifson JD, Reyes GR, McGrath MS, Stein BS, Engleman EG (1986) AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen Sci- ence 232:1123-1127Google Scholar
  58. Linial M (2000) Why aren't foamy viruses pathogenic? Trends Microbiol 8:284-289 Linial ML, Miller AD (1990) Retroviral RNA packaging: sequence requirements and implications. Curr Topics Micro Immunol 157:125-185Google Scholar
  59. Löchelt M, Flügel RM, Aboud M (1994) The human foamy virus internal promoter directs the expression of the functional Bel 1 and Bet protein early after infection. J Virol 68:638-645PubMedGoogle Scholar
  60. Löchelt M, Muranyi W, Flügel RM (1993) Human foamy virus genome posses an internal, Bel-1-dependent and functional promoter. Proc Natl Acad Sci USA 90:7317-7321PubMedGoogle Scholar
  61. Löchelt M, Zentgraf H, Flügel RM (1991) Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel 1 gene. Virology 184:43-54PubMedGoogle Scholar
  62. Mann R, Mulligan RC, Baltimore D (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153-159PubMedGoogle Scholar
  63. Maurer B, Bannert H, Darai G, Flügel RM (1988) Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretro- virus. J Virol 62:1590-1597PubMedGoogle Scholar
  64. McCann EM, Lever AM (1997) Location of cis-acting signals important for RNA encapsidation in the leader sequence of human immunodeficiency virus type 2. J Virol 71:4133-4137PubMedGoogle Scholar
  65. Meiering CD, Comstock KE, Linial ML (2000) Multiple integrations of human foamy virus in persistently infected human erythroleukemia cells. J Virol 74:1718-1726PubMedGoogle Scholar
  66. Mergia A (1994) Simian foamy virus type 1 contains a second promoter located at the 3' end of the env gene. Virology 199:219-222PubMedGoogle Scholar
  67. Mergia A, Chari S, Kolson DL, Goodenow MM, Ciccarone T (2001) The efficiency of simian foamy virus vector type-1 (SFV-1) in nondividing cells and in human PBLs. Virology 280:243-252PubMedGoogle Scholar
  68. Mergia A, Leung NJ, Blackwell J (1996) Cell tropism of the simian foamy virus type 1 (SFV-1). J Med Primatol 25:2-7PubMedGoogle Scholar
  69. Mergia A, Luciw PA (1991) Replication and regulation of primate foamy viruses. Virology 184:475-482PubMedGoogle Scholar
  70. Mergia A, Pratt-Lowe E, Shaw KE, Renshaw-Gegg LW, Luciw PA (1992) cis-Acting regulatory regions in the long terminal repeat of simian foamy virus type 1. J Virol 66:251-257PubMedGoogle Scholar
  71. Mergia A, Shaw KE, Pratt-Lowe E, Barry PA, Luciw PA (1991) Identification of the simian foamy virus transcriptional transactivator gene (taf). J Virol 65:2903-2909PubMedGoogle Scholar
  72. Mergia A, Wu M (1998) Characterization of provirus clones of simian foamy virus type 1 (SFV-1). J Virol 72:817-822PubMedGoogle Scholar
  73. Miele G, Mouland A, Harrison GP, Cohen E, Lever AM (1996) The human immunodeficiency virus type 1 5“ packaging signal structure affects translation but does not function as an internal ribosome entry site structure. J Virol 70:944-951PubMedGoogle Scholar
  74. Mikovits JA, Hoffman PM, Rethwilm A, Ruscetti FW (1996) In vitro infection of primary and retrovirus-infected human leukocytes by human foamy virus. J Virol 70:2774-2780PubMedGoogle Scholar
  75. Miller AD (1992) Human gene therapy comes of age. Nature 357:455-460PubMedGoogle Scholar
  76. Miller AD, Buttimore C (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6:2895-2902PubMedGoogle Scholar
  77. Miller DG, Adam MA, Miller AD (1990) Gene transfer by retroviral vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239-4242PubMedGoogle Scholar
  78. Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, Bock M, McClure MO, Rethwilm A (1997) Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 71:7305-11PubMedGoogle Scholar
  79. Morgan RA, Blaese RM (1999) Gene therapy: lessons learnt from the past decade. BMJ 319:1310-12PubMedGoogle Scholar
  80. Mountain A (2000) Gene therapy: the first decade. Trends Biotechnol 18:119-128PubMedGoogle Scholar
  81. Muranyi W, Flügel RM (1991) Analysis of splicing patterns of human spumaretro- virus by polymerase chain reaction reveals complex RNA structures. J Virol 65:727-735PubMedGoogle Scholar
  82. Naldini L, Blomer U, Gage FH, Trono D, Verma IM (1996a) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93:11382-11388PubMedGoogle Scholar
  83. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996b) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267PubMedGoogle Scholar
  84. Naviaux RK, Costanzi E, Haas M, Verma IM (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70:5701-5705PubMedGoogle Scholar
  85. Nestler U, Heinkelein M, Lucke M, Meixensberger J, Scheurlen W, Kretschmer A, Rethwilm A (1997) Foamy virus vectors for suicide gene therapy. Gene Ther 4:1270-1277PubMedGoogle Scholar
  86. Neumann-Haefelin D, Schweizer M, Corsten B, Matz B (1986) Detection and characterization of infectious DNA intermediates of a primate foamy virus. J Gen Virol 67:1993-1999PubMedGoogle Scholar
  87. Paillart JC, Berthoux L, Ottmann M, Darlix JL, Marquet R, Ehresmann B, Ehresmann C (1996) A dual role of the putative RNA dimerization initiation site of human immunodeficiency virus type 1 in genomic RNA packaging and proviral DNA synthesis. J Virol 70:8348-8354PubMedGoogle Scholar
  88. Park J, Mergia A (2000) Mutational analysis of the 5' leader region of simian foamy virus type 1. Virology 274:203-212PubMedGoogle Scholar
  89. Park J, Nadeau PE, Mergia A (2002) A minimal genome simian foamy virus type 1 (SFV-1) vector system with efficient gene transfer. Virology 302: 236-244PubMedGoogle Scholar
  90. Poeschla EM, Wong-Staal F, Looney DJ (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4:354-357PubMedGoogle Scholar
  91. Renne R, Mergia A, Renshaw-Gegg LW, Neumanm-Haefelin D, Luciw PA (1993) Regulatory elements in the long terminal repeat (LTR) of simian foamy virus type 3. Virol 192:365-369Google Scholar
  92. Renshaw RW, Casey JW (1994a) Analysis of the 5 ' long terminal repeat of bovine syncytial virus. Gene 141:221-224PubMedGoogle Scholar
  93. Renshaw RW, Casey JW (1994b) Transcriptional mapping of the 3' end of the bovine syncytial virus genome. J Virol 68:1021-1028PubMedGoogle Scholar
  94. Rethwilm A, Baunach G, Netzer K-O, Maurer B, Borisch B, ter Maulen V (1990) In- fectious DNA of the human spumaretrovirus. Nucleic Acids Res 18:733-738PubMedGoogle Scholar
  95. Rethwilm A, Erlwein O, Baunach G, Maurer B, ter Meulen V (1991) The transcrip- tional transactivator of human foamy virus maps to the bel 1 genomic region. Proc Natl Acad Sci USA 88:941-945PubMedGoogle Scholar
  96. Robbins P, Tahara H, Ghivizzani S (1998) Viral vectors for gene therapy. Trends Biotechnol 16:35-40PubMedGoogle Scholar
  97. Rochlitz CF (2001) Gene therapy of cancer. Schweiz Med Wochenschr 131:4-9Google Scholar
  98. Roe T, Reynolds TC, Yu G, Brown PO (1993) Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12:2099-2108PubMedGoogle Scholar
  99. Romano G, Micheli P, Pacilio C, Giordano A (2000) Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18:19-39PubMedGoogle Scholar
  100. Russell DW, Miller AD (1996) Foamy virus vectors. J Virol 70:217-22PubMedGoogle Scholar
  101. Russell RA, Zeng Y, Erlwein O, Cullen BR, McClure MO (2001) The R region found in the human foamy virus long terminal repeat is critical for both Gag and Pol protein expression. J Virol 75:6817-6824PubMedGoogle Scholar
  102. Saib A, Koken MH, van der Spek P, Perks J, de The H (1995) Involvement of a spliced and defective human foamy virus in the establishment of chronic infection. J Virol 69:5261-5268PubMedGoogle Scholar
  103. Saib A, Puvion-Dutilleul F, Schmid M, Perks J, de The H (1997) Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 71:1155-61PubMedGoogle Scholar
  104. Sandstrom PA, Phan KO, Switzer WM, Fredeking T, Chapman L, Heneine W, Folks TM (2000) Simian foamy virus infection among zoo keepers. Lancet 355:551-552PubMedGoogle Scholar
  105. Schenk T, Enssle J, Fischer N, Rethwilm A (1999) Replication of a foamy virus mu- tant with a constitutively active U3 promoter and deleted accessory genes. J Gen Virol 80:1591-1598PubMedGoogle Scholar
  106. Schmidt M, Niewiesk S, Heeney J, Aguzzi A, Rethwilm A (1997) Mouse model to study the replication of primate foamy viruses. J Gen Virol 78:1929-1933PubMedGoogle Scholar
  107. Schmidt M, Rethwilm A (1995) Replicating foamy virus-based vectors directing high level expression of foreign genes. Virology 210:167-178PubMedGoogle Scholar
  108. Schnell T, Foley P, Wirth M, Munch J, Uberla K (2000) Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11:439-447PubMedGoogle Scholar
  109. Schweizer M, Falcone V, Gange J, Turek R, Neumann-Haefelin D (1997) Simian foamy virus isolated from an accidentally infected human individual. J Virol 71:4821-4824PubMedGoogle Scholar
  110. Schweizer M, Turek R, Hahn H, Schliephake A, Netzer KO, Eder G, Reinhardt M, Rethwilm A, Neumann-Haefelin D (1995) Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retroviruses 11:161-170PubMedGoogle Scholar
  111. Smith A (1999) Gene Therapy-where are we? Lancet 354:1-4Google Scholar
  112. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA (1986) Role of the HTLV- III/LAV envelope in syncytium formation and cytopathicity. Nature 322:470-474PubMedGoogle Scholar
  113. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23:628-633PubMedGoogle Scholar
  114. Springett GM, Moen RC, Anderson S, Blaese RM, Anderson WF (1989) Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol 63:3865-3869PubMedGoogle Scholar
  115. Tobaly-Tapiero J, Bittoun P, Neves M, Guillemin MC, Lecellier CH, Puvion-Dutilleul F, Gicquel B, Zientara S, Giron ML, de The H, Saib A (2000) Isolation and characterization of an equine foamy virus. J Virol 74:4064-4073PubMedGoogle Scholar
  116. Tobaly-Tapiero J, Kupiec J-J, Santillana-Hayat M, Canivet M, Peries J, Emanoil-Ravier R (1991) Further characterization of the gapped DNA intermediates of human spumavirus: evidence for a dual initiation of plus-stranded DNA synthesis. J Gen Virol 72:605-608PubMedGoogle Scholar
  117. Trobridge GD, Russel DW (1998) Helper-free foamy virus vectors. Hum Gene Ther 9:2517-2525PubMedGoogle Scholar
  118. Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW (2002a) Improved foamy virus vectors with minimal viral sequences. Mol Ther 6:321-328PubMedGoogle Scholar
  119. Trobridge G, Vassilopoulos G, Josephson N, Russell DW (2002b) Gene transfer with foamy virus vectors. Methods Enzymol 346:628-648PubMedGoogle Scholar
  120. Varmus H (1988) Retroviruses. Science 240:1427-1435PubMedGoogle Scholar
  121. Vassilopoulos G, Trobridge G, Josephson NC, Russell DW (2001) Gene transfer into murine hematopoietic stem cells with helper free foamy virus vectors. Blood 98:604-609PubMedGoogle Scholar
  122. Venkatesh LK, Theodorakis PA, Chinnadurai G (1991) Distinct cis-acting regions in the U3 regulate trans-activation of the human spumaretrovirus long terminal repeat by the viral bell gene product. Nucl Acids Res 19:3661-3666PubMedGoogle Scholar
  123. von-Laer D, Neumann-Haefelin D, Heeney J, Schweizer M (1996) Lymphocytes are the major reservoir for foamy viruses in peripheral blood. Virology 221:240-244PubMedGoogle Scholar
  124. Weiss RA (1988) Foamy retroviruses. A virus in search of a disease. Nature 333:497-8PubMedGoogle Scholar
  125. Winkler I, Bodem J, Haas L, Zemba M, Delius H, Flower R, Flügel RM, Löchelt M (1997) Characterization of the genome of feline foamy virus and its proteins shows distinct features different from those of primate spumaviruses. J Virol 71:6727-6741PubMedGoogle Scholar
  126. Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, Marconi PC, Fink DJ, Glorioso JC (1999) Engineering herpes simplex virus vectors for CNS applications. Exp Neurol 159:34-36PubMedGoogle Scholar
  127. Wu M, Chan S, Yanchis T, Mergia A (1998) Cis-acting sequences required for simian foamy virus type 1 (SFV-1) vectors. J Virol 72:3451-3454PubMedGoogle Scholar
  128. Wu M, Mergia A (1999) Packaging cell lines for simian foam virus type 1 (SFV-1) vectors. J Virol 73:4498-4501PubMedGoogle Scholar
  129. Wu N, Ataai M (2000) Production of viral vectors for Gene Ther applications. Curr Opin Biotech 11:205-208PubMedGoogle Scholar
  130. Yee JK, Friedmann T, Burns JC (1994) Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43:99-112PubMedGoogle Scholar
  131. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T (1994) A general method for the generation of high-titer, pantropic retroviral vectors• highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 91:9564-9568PubMedGoogle Scholar
  132. Yu H, Rabson AB, Kaul M, Ron Y, Dougherty JP (1996) Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 70:4530-4537PubMedGoogle Scholar
  133. Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, Linial ML (1996) Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses. Science 271:1579-1582PubMedGoogle Scholar
  134. Yu SF, Linial ML (1993) Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay. J Virol 67:6618-6624PubMedGoogle Scholar
  135. Yu SF, Sullivan MD, Linial ML (1999) Evidence that the human foamy virus genome is DNA. J Virol 73:1565-1572PubMedGoogle Scholar
  136. Zennou V, Petit C, Guetard D, Nehrbass U, Montgnier L, Chameau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173-185PubMedGoogle Scholar
  137. Zucali JR, Ciccarone T, Kelley V, Johnson CM, Mergia A (2002) Transduction of umbilical cord blood CD34+ NOD/SCID repopulating cells by simian foamy virus type 1 (SFV-1) vector. Virology 302:229-235PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  1. 1.Department of Pathobiology, College of Veterinary MedicineUniversity of FloridaGainesvilleUSA
  2. 2.Institut für Virologie und ImmunbiologieUniversität WürzburgWürzburgGermany

Personalised recommendations